ASX ANNOUNCEMENT
15 October 2008

PRESENTATIONS AT FORTHCOMING MEDICAL CONFERENCES

Framingham, MA and Sydney, Australia, 15 October, 2008 - HeartWare Limited (ASX: HTW) advises that this week, two of the principal investigators in the US clinical trial of the HeartWare® Left Ventricular Assist System will be delivering presentations at important clinical meetings.

On Tuesday 14th October (USA Eastern time), Dr. Steven Boyce will present at the TCT (Transcatheter Cardiovascular Therapeutics) Conference in Washington. The title of Dr. Boyce's presentation is "The HeartWare Miniaturized Intrapericardial HVAD". Dr Boyce is Surgical Director of the Heart Failure Program at Washington Hospital Center. He conducted the first implant of the HeartWare® Left Ventricular Assist System in the United States.

On Saturday 18th October, Dr. Mark Slaughter will present at the Cleveland Clinic Heart Failure Meeting. He will present an overview of the HeartWare technology and clinical results during a session titled "Contemporary Experience with New Pumps". Dr. Slaughter is Professor of Surgery and Chief of the Division of Thoracic and Cardiovascular Surgery at the University of Louisville. He serves as the Director of the Heart Transplant and Mechanical Assist Device program at Jewish Hospital and the University of Louisville and is the Associate Medical Director of the Cardiovascular Innovation Institute.

Specific Congress Session Details:

TCT Conference - Tuesday October 14 at 4:41 PM (EST). Session IV, *LVADs for Long-Term Support*.

Cleveland Clinic Heart Failure Meeting - Saturday , October 18 from 3:10 – 4:45 PM (EST) Session VIII, *Contemporary Experience with New Pumps*.

Following these presentations, copies of the presentation materials will be released and will be available from the HeartWare website.

About HeartWare

HeartWare develops and manufactures miniaturized implantable heart pumps, or Left Ventricular Assist Devices (LVADs), to treat patients suffering from advanced heart failure. The HeartWare® LVAD is the only full-output pump designed to be implanted in the chest, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has completed an international clinical trial for the device involving five investigational centres in Europe and Australia. The device is currently the subject of a 150-patient clinical trial in the United States for a Bridge-to-Transplant indication.

For further information:

www.heartware.com.au
Howard Leibman
Director Corporate Development
HeartWare Limited
Email. howard.leibman@heartware.com.au
Tel. +61 2 9238 2064

US Investor Relations
Matt Clawson
Partner
Allen & Caron, Inc.
Email. matt@allencaron.com
Tel. +1 949 474 4300

Forward-Looking Statements

This announcement contains forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the progress of clinical trials. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including without limitation those described in "Item 1A. Risk Factors" in our Annual Report on Form 10-K filed with the SEC on February 28, 2008, and those described in other reports filed from time to time with the SEC.